InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches a new data annotation service designed to support researchers and analysts who require specific, literature-based biological data for use in QSP modeling, analysis, or decision-making.
The new service allows clients to submit targeted data requests related to diseases, tissues, cell types, and cytokines. InSysBio team will populate its CYTOCON or fIVE databases with newly curated data, ensuring availability in the most convenient and standardized format for subsequent analysis and integration.
Key features of the deliverables (all integrated into CYTOCON DB and fIVE DB):
1. Annotated Data Tables:
2. Summary Statistics Table
3. Visualizations
Each data request follows a one-month workflow. The first week is dedicated to a feasibility assessment, during which the team evaluates the availability and volume of the requested data in scientific literature. If the data cannot be identified, clients receive detailed feedback, and the query may be refined. Depending on the scope and complexity of the request, the team can process up to 20 scientific articles per month, resulting in approximately 800 annotated concentration values for CYTOCON DB and 130 annotated parameters for fIVE DB. All annotations are performed by a dedicated team consisting of one professional annotator and one reviewer, ensuring a high standard of quality and consistency throughout the process.
For further details or to data request, please feel free to contact us: support@insysbio.com
To learn more about CYTOCON DB, please visit https://cytocon.insysbio.com/Index.aspx
To learn more about fIVE DB, please visit https://5db.insysbio.com/Index.aspx
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | September 2024 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
| ||||||
|
2
|
3
|
4
1.
04 Sep 2024 16:07
Now B cells model reflects the current views on the processes
InSysBio launches Immune Response Template (IRT) version 3.6.3. IRT represents a QSP platform of immune system, simultaneously, being a tool for development of models related to immune system
|
5
|
6
|
7
|
8
|
|
9
|
10
1.
10 Sep 2024 18:36
InSysBio team to publish the new article in PSPJournal
The new article "Quantitative systems pharmacology model of α-synuclein pathology in Parkinson's disease-like mouse for investigation of passive immunotherapy mechanisms" by Olga Ivanova and Tatiana Karelina was published in PSPJournal at the end of August 2024
|
11
1.
11 Sep 2024 15:25
InSysBio to take part in ACoP 2024
InSysBio announces its participation in the 15th American Conference on Pharmacometrics (ACoP). Oleg Demin Jr, Scientific Director, Oncology & Immuno-Oncology, will be a co-chair and speaker of the session "Advancing QSP: From Virtual Patient To Digital Twin". InSysBio team is going to present its modeling services & software to optimize drug development at the Booth #11 and 9 posters in frames of the Conference
|
12
|
13
|
14
|
15
|
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
|
30
| ||||||